Table 5. Demographic and clinical baseline status between Helicobacter pylori (HP) positive patients who succeeded and failed the eradication therapy.
| Successful eradication (n = 17) | Failure eradication (n = 5) | P | |
|---|---|---|---|
| Male gender, n (%) | 7 (41.2) | 5 (100.0) | 0.020 |
| Age (years) | 61.1 ± 10.6 | 57.4 ± 9.8 | 0.495 |
| Age at onset (years) | 53.3 ± 10.3 | 50.4 ± 9.5 | 0.544 |
| Smoking, n (%) | 0 (0.0) | 2 (40.0) | 0.006 |
| Vegetable/fruit (servings/day) | 2.4 ± 0.6 | 1.4 ± 0.9 | 0.009 |
| Disease duration (years) | 7.6 ± 4.2 | 7.0 ± 5.5 | 0.834 |
| SE-ADL | 77.1 ± 4.7 | 80 ± 0.0 | 0.184 |
| Hoehn & Yahr stage | 2.2 ± 0.6 | 2.2 ± 0.3 | 0.976 |
| ‘Off’ UPDRS motor score | 31.3 ± 10.9 | 33.0 ± 6.2 | 0.664 |
| ‘On’ UPDRS motor score | 13.5 ± 7.5 | 17.2 ± 7.6 | 0.370 |
| Total LED (mg/day) | 774.3 ± 312.7 | 617.9 ± 156.9 | 0.152 |
| • Dopamine agonist, n (%) | 14 (82.4) | 5 (100.0) | 0.312 |
| • COMT inhibitor, n (%) | 9 (52.9) | 1 (20.0) | 0.193 |
| • MAO-B inhibitor, n (%) | 1 (5.9) | 1 (20.0) | 0.334 |
| • Anticholinergic use, n (%) | 6 (35.3) | 1 (20.0) | 0.519 |
SE-ADL: Schwab and England Activities of Daily Living Scale; UPDRS: Unified Parkinson’s Disease Rating Scale; LED: Levodopa equivalent dose; COMT: catechol-O-methyltransferase; MAO: Monoamine oxidase.
Statistically significant p-values are in bold.